{"title":"[Citrate therapy in treating urate nephrolithiasis].","authors":"N F Sergienko, L V Shaplygin, S F Kuchits","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Citrate therapy was tried in 483 patients with urate nephrolithiasis. A good response was obtained both in monotherapy or in combination of urates with invasive or remote treatment. The authors advocate the drug blemaren (ESPARMA, Germany) as most beneficial among citrate drugs.</p>","PeriodicalId":23468,"journal":{"name":"Urologiia i nefrologiia","volume":" 2","pages":"34-6"},"PeriodicalIF":0.0000,"publicationDate":"1999-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urologiia i nefrologiia","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Citrate therapy was tried in 483 patients with urate nephrolithiasis. A good response was obtained both in monotherapy or in combination of urates with invasive or remote treatment. The authors advocate the drug blemaren (ESPARMA, Germany) as most beneficial among citrate drugs.